Diagnosis & Disease Information

The effect of MYD88 and CXCR4 mutations on therapy response among patients with treatment-naïve Waldenström macroglobulinemia requires further investigation.

A better understanding of current practices may lead to improved, standardized care, as well as better use of health care resources in Waldenström macroglobulinemia.

The effectiveness of ibrutinib in the frontline setting has not been definitively established.

Previous studies have shown that acalabrutinib monotherapy may lead to improved outcomes among patients with treatment-naive or relapsed/refractory Waldenstrom macroglobulinemia.

The impact of dose-intensity reduction in Waldenstrom macroglobulinemia has not been explored.

The median progression-free survival was not reached after a median follow-up of 22 months.

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.

In patients with R/R WM, the overall response rate was 87%, with 4% of patients achieving a very good partial response.